Compare Regeneron Pharmaceuticals Inc (REGN) vs Vanguard International High Dividend Yield ETF (VYMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Vanguard International High Dividend Yield ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.14B), while Vanguard International High Dividend Yield ETF trades at $102.18 (market cap $22.80B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 3.3× Vanguard International High Dividend Yield ETF's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Vanguard International High Dividend Yield ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Vanguard International High Dividend Yield ETF for 50 Days on average.
| REGN | VYMI | |
|---|---|---|
Market Cap | $76.14B | $22.80B |
Volume | 500,239 | 748,441 |
Sector | Health | Broad Market / Factor |
52-Week High | $852.03 | $107.13 |
52-Week Low | $557.73 | $82.92 |
Typical Hold Time | 107 Days | 50 Days |
Enterprise Value | $70.85B | — |
Dividend Yield | 0.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.
The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.
VYMI trades at $100.23, down 1.11% today amid bearish technical signals. The ETF shows strong institutional interest with multiple firms increasing holdings recently. Recent analysis highlights VYMI's 5-year average annual return of 14.13% and 3.61% dividend yield, outperforming peers despite current technical weakness.
The outlook remains positive given VYMI's exposure to international dividend stocks benefiting from higher global rates. Key risks include currency fluctuations and concentrated financial sector exposure. Analyst sentiment leans bullish with expectations of continued international stock outperformance versus US markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Vanguard International High Dividend Yield ETF
VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →
